Healthcare Stocks Jump 9.5% in October as Tech Crashes

Healthcare stocks gained 9.53% in October 2026, making the sector one of the month's clear winners while technology shares suffered their worst month since March 2025. The Health Care Select Sector SPDR Fund (XLV) rose 9.53% for the month and closed at $184.87 on Friday, October 30 — up 0.45% on a day when the Nasdaq Composite fell 2.86%.

What happened in October?

October split Wall Street in two. The Nasdaq Composite lost 5.3% for the month, and the S&P 500's information-technology sector dropped 6.8%, its worst month since March 2025, according to FactSet data reported by MarketWatch. Healthcare moved the other way. Money rotated out of high-flying artificial-intelligence and semiconductor names and into drugmakers, insurers and medical companies with established cash flows — businesses investors treat as defensive when growth stocks get expensive and volatile.

The gap was visible right down to the final session. On Friday, as Intel and other chip stocks dragged the Nasdaq to its steepest daily fall since June, XLV finished in positive territory and Gilead Sciences jumped 4.26% to $172.67 after a strong earnings report.

Which healthcare stocks led the rally?

Regeneron Pharmaceuticals was the sector's biggest October winner, rising 26.28% after third-quarter results beat expectations, with revenue up about 36% year over year, driven by its collaboration with Sanofi. Charles River Laboratories gained 25.30% for the month. Eli Lilly rose 23.28% after better-than-expected results and a higher full-year revenue outlook, powered by demand for its Mounjaro and Zepbound medicines. GE HealthCare added 19.68% in October.

Not every healthcare name joined in. Illumina was the sector's biggest detractor on Seeking Alpha's October scorecard, slipping 11.19% after its quarterly revenue missed expectations despite a profit beat, and Solventum declined 7.34%.

Why is the healthcare rally blowing up now?

Three forces came together. First, the AI trade cracked: Big Tech earnings raised hard questions about whether massive data-center spending will pay off, and investors looked for sectors less dependent on that spending. Second, healthcare earnings delivered. Lilly, Regeneron and Gilead all beat expectations and raised or confirmed strong outlooks during the month, giving the rotation somewhere solid to land. Third, healthcare had been the cheaper, steadier corner of the market — exactly what portfolios reach for when the VIX jumps and momentum stocks swing by double digits in a day.

Gilead's Friday report summed up the pattern. The company posted adjusted earnings of $2.55 a share, ahead of the $2.19 consensus, on revenue of $8.30 billion, up 6.8% year over year. HIV product sales rose 18% to $6.25 billion, and cancer drug Trodelvy sales jumped 42%. Gilead also raised its full-year product-sales guidance to $31.0 billion to $31.3 billion, up from $30.1 billion to $30.4 billion.

Key facts

• XLV, the main U.S. healthcare sector fund, gained 9.53% in October and closed the month at $184.87.
• The Nasdaq Composite fell 5.3% in October, its worst month since March 2025; S&P 500 technology stocks fell 6.8%.
• October's top healthcare gainers: Regeneron +26.28%, Charles River Laboratories +25.30%, Eli Lilly +23.28%, GE HealthCare +19.68%.
• Gilead beat earnings on Friday and raised its 2026 product-sales outlook, finishing the month up 4.26% on the day.
• Illumina (-11.19%) and Solventum (-7.34%) were the sector's main October laggards.

What's next?

The test comes quickly. Apple reports on Monday, November 2, U.S. midterm elections follow on Tuesday, and the October jobs report lands on Friday — a week that could either revive the tech trade or deepen the rotation. Healthcare's own bar is also higher now: after a near-10% month, the sector no longer trades as the market's overlooked bargain, and upcoming results from insurers and drugmakers will need to keep beating expectations to hold the gains. For now, October's message is simple: when AI stocks wobbled, investors paid up for earnings they could already see.

Sources: Seeking Alpha, TradingView, TokenPost, MarketWatch, Zacks

FAQ

How much did healthcare stocks gain in October 2026?

The Health Care Select Sector SPDR Fund (XLV) gained 9.53% in October 2026, closing the month at $184.87, while the Nasdaq Composite fell 5.3%.

Which healthcare stock rose the most in October?

Regeneron Pharmaceuticals led the sector with a 26.28% October gain after third-quarter revenue rose about 36% year over year and beat expectations.

Why did investors rotate into healthcare stocks?

Investors moved out of expensive, volatile AI and technology shares and into healthcare companies with steadier cash flows and earnings that were beating expectations.

Did every healthcare stock rise in October?

No. Illumina fell 11.19% after a revenue miss and Solventum fell 7.34%, even as the wider sector rallied almost 10%.